CHARLES M. BAGLEY JR., M.D.; ROBERT H. RUDOLPH, M.D.; SAUL E. RIVKIN, M.D.; JOSEPH L. YON JR., M.D.
To the editor: We wish to call to your readers' attention an unexpectedly severe and disabling neurotoxicity due to very-high-dose cisplatin therapy for cancer of the ovary. The attainment of complete remission, proven by second-look surgery, is the first step toward achieving prolonged survival and cure of stage III cancer of the ovary. Recently, Ozols and associates (1) have reported that administration of very high doses of cisplatin (200 mg/m2 body surface area over 5 consecutive days) has achieved frequent tumor regression in patients with advanced cancer of the ovary previously refractory to conventional doses of cisplatin. To improve complete
CHARLES M. BAGLEY, ROBERT H. RUDOLPH, SAUL E. RIVKIN, JOSEPH L. YON. High-Dose Cisplatin Therapy for Cancer for the Ovary: Neurotoxicity. Ann Intern Med. 1985;102:719. doi: 10.7326/0003-4819-102-5-719
Download citation file:
Published: Ann Intern Med. 1985;102(5):719.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use